* Plans to initiate early-stage trial by mid-year
* Shares up 13 pct in after-market
April 26 (Reuters) - Dynavax Technologies Corp DVAX.O said its vaccine against flu showed positive response in a preclinical study, sending its shares up 13 percent.
Dynavax’s vaccine enhances the efficacy of a standard flu vaccine by increasing antibody production, the company said.
The company plans to initiate early-stage clinical development of its universal flu vaccine by mid-year 2010.
Shares of the company were up 16 cents at $1.60 in after-market trade. They closed at $1.44 Monday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Don Sebastian)
Our Standards: The Thomson Reuters Trust Principles.